Skip to content

Clinical Study on external application of Tongbi Tuomin ointment in treatment of allergic rhinitis in children

Clinical Study on external application of Tongbi Tuomin ointment in treatment of allergic rhinitis in children

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2200005658
Enrollment
Unknown
Registered
2022-02-23
Start date
2022-02-24
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis in children

Interventions

Blank Group:Vaseline ointment for external use
External Group:Nasal desensitization ointment for external use
Oral Group:Take basic prescription decoction of traditional Chinese medicine

Sponsors

Nanjing University of Chinese Medicine Affiliated Hospital(Jiangsu Provincial Hospital of traditional Chinese medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 18 Years

Inclusion criteria

Inclusion criteria: (1) those who meet the above diagnostic criteria of western medicine; (2) those who are between 1 and 18 years of age and of any sex; (3) those who give informed consent and volunteer to be tested. The process of obtaining an informed consent shall be in accordance with the GCP.

Exclusion criteria

Exclusion criteria: (1) children with severe complications, such as asthma attack, severe nasal polyp affecting breathing, significant deviated Septum, and sleep apnea syndrome requiring surgical treatment; (2) children with upper respiratory tract infection; (3) patients with primary diseases such as heart, brain, blood vessel, liver, kidney and hematopoiesis; (4) those who are undergoing desensitization treatment; (5) those who are allergic to the ingredients of this traditional Chinese medicine; (6) those who have received relevant drug treatment and surgery within one week of the onset of this allergic rhinitis. (7) patients participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
Metabonomics product;

Countries

China

Contacts

Public ContactZhao Xia
zhaoxiahy@126.com13915994006

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026